阿昔替尼联合塞来昔布体外抗胃癌细胞BGC-823和SNU-5增殖及抗血管生成作用观察
Combination efficacy of axitinib and celecoxib on proliferation of gastric cancer cells BGC-823 and SNU-5 and its antiangiogenesis effect

目的:探索阿昔替尼(Ax)和塞来昔布(Cel)在胃癌细胞株BGC-823和SNU-5的联合效应及对新生血管形成的影响。方法:SRB法测定10 nmol/L Cel和1 nmol/L Ax以及联合用药对BGC-823细胞增殖的抑制作用,CCK-8法检测Cel和Ax以及联合用药对SNU-5细胞增殖的抑制作用,Matrial胶体外管腔形成法检测药物对于新生血管的影响。结果:在BGC-823和SNU-5细胞株中,Cel和Ax单药均可抑制BGC-823和SNU-5细胞的增殖,联合用药组的细胞生长抑制率高于Cel和Ax单药组,联合用药指数＜1。Cel和Ax单药组对HUVEC细胞的管腔形成系数分别为(0.86±0.03)和(0.83±0.01),联合这2种药物之后,管腔形成系数下降为(0.67±0.02)(P＜0.05)。结论:Cel和Ax的联合用药方案不仅比单一用药有更高的细胞生长抑制率,并且还具有协同抑制新生血管形成的作用。
Aim: To explore the combination efficacy of axitinib(Ax)and celecoxib(Cel)on the proliferation of gastric cancer cell lines BGC-823 and SNU-5 and antiangiogenesis effect.Methods: SRB and CCK-8 methods were used to assess the effect of 10 nmol/L Cel and 1 nmol/L Ax on the proliferation of BGC-823 and SNU-5,respectively. Capillary formation was detected by Matrial-plug assay in vitro.Results: SRB and CCK-8 assay showed that Cel and Ax inhibited the proliferation of BGC-823 and SNU-5. The inhibitory rate of combined treatment with Cel and Ax was significantly higher than that of Cel or Ax alone,and the combination index was lower than 1. The vascular indexes of HUVEC treated by Cel and Ax were(0.86±0.03)and(0.83±0.01), respectively, while the combined treatment group was(0.67±0.02)(P＜0.05).Conclusion: The combination therapy of Ax and Cel reveals synergetic effect not only in the cell proliferation but also in angiogenesis inhibition